Pharmacoeconomical analysis of protease inhibitors which are applied to treatment of HIV patients in Ukraine. R e p o r t II.
Pharmacoeconomical analysis of protease inhibitors which are applied to treatment of treatment experienced patients
Keywords:
HIV/AIDS, treatment experienced HIV patients, protease inhibitors: darunavir, lopinavir, nelfinavir, ritonavir, cost-effectiveness analysis
Abstract
The comparative «cost-effectiveness» analysis of ART which include protease inhibitors is carried out. Application of a combination ofpreparations darunavir/ritonavir schemes ART treatment experienced HIV patients is proved.
References
1. Order of the Ministry of Health of Ukraine No. 551 of 12.07.10 "On approval of the clinical protocol of antiretroviral therapy of HIV infection in adults and adolescents".
2. Christine Katlama et al. Efficacy and Safety of TMC114 / ritonavir in Treatment-Experienced HIV Patients: 24-Week Results of POWER 1. AIDS. 2007; 21 (4): 395-402.
3. Bonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, David Cooper, Jean-Christophe Goffard, Adriano Lazzarin, Andrej Wohrmann, Christine Katlama, Timothy Wilkin, Richard Haubrich, Calvin Cohen, Charles Farthing, Dushyantha Jayaweera, Martin Markowitz, Peter Ruane , Sabrina Spinosa-Guzman, Eric Lefebvr (on behalf of the POWER Study Groups 1 and 2) Reprints. The efficacy and safety of the darunavir-ritonavir combination evaluated at week 48 in studies
POWER 1 and POWER 2 in patients with HIV-1 who have previously received antiretroviral therapy: a combined subgroup analysis of data from two randomized trials // Lancet 2007; 369: 1169-78.
4. Arastéh K, Yeni P, Pozniak A, Grinsztein B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka E. Efficacy and safety of darunavir / ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009; 14 (6): 859-64.
5. A Pozniak, K Arastéh, JM Molina, Grinsstein, S De Meyer, T Van De Casteele, S Spinosa-Guzman POWER 3 analysis: 144-week efficacy and safety results for darunavir / ritonavir (DRV / r) 600/100 mg BID in treatment-experienced HIV patients (Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9-13 November 2008) // Journal of the International AIDS Society 2008, 11 (Suppl 1): P24doi: 10.1186 / 1758- 2652-11-Sl-P24 Access Mode http: //www.jiasociety. org / coutent / 11 / S1 / P24.
6. Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8 (7): 439-50.
7. Madruga J.V. et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet. 2007; 370: 49 58.
8. Curran A, Ribera Pascuet E. Darunavir as first-line therapy. The TITAN study Enferm Infecc Microbiol Clin. 2008 Oct; 26 Suppl 10:14.
2. Christine Katlama et al. Efficacy and Safety of TMC114 / ritonavir in Treatment-Experienced HIV Patients: 24-Week Results of POWER 1. AIDS. 2007; 21 (4): 395-402.
3. Bonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, David Cooper, Jean-Christophe Goffard, Adriano Lazzarin, Andrej Wohrmann, Christine Katlama, Timothy Wilkin, Richard Haubrich, Calvin Cohen, Charles Farthing, Dushyantha Jayaweera, Martin Markowitz, Peter Ruane , Sabrina Spinosa-Guzman, Eric Lefebvr (on behalf of the POWER Study Groups 1 and 2) Reprints. The efficacy and safety of the darunavir-ritonavir combination evaluated at week 48 in studies
POWER 1 and POWER 2 in patients with HIV-1 who have previously received antiretroviral therapy: a combined subgroup analysis of data from two randomized trials // Lancet 2007; 369: 1169-78.
4. Arastéh K, Yeni P, Pozniak A, Grinsztein B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka E. Efficacy and safety of darunavir / ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009; 14 (6): 859-64.
5. A Pozniak, K Arastéh, JM Molina, Grinsstein, S De Meyer, T Van De Casteele, S Spinosa-Guzman POWER 3 analysis: 144-week efficacy and safety results for darunavir / ritonavir (DRV / r) 600/100 mg BID in treatment-experienced HIV patients (Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9-13 November 2008) // Journal of the International AIDS Society 2008, 11 (Suppl 1): P24doi: 10.1186 / 1758- 2652-11-Sl-P24 Access Mode http: //www.jiasociety. org / coutent / 11 / S1 / P24.
6. Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8 (7): 439-50.
7. Madruga J.V. et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet. 2007; 370: 49 58.
8. Curran A, Ribera Pascuet E. Darunavir as first-line therapy. The TITAN study Enferm Infecc Microbiol Clin. 2008 Oct; 26 Suppl 10:14.
Published
2019-10-29
How to Cite
Boyko, A. (2019). Pharmacoeconomical analysis of protease inhibitors which are applied to treatment of HIV patients in Ukraine. R e p o r t II.: Pharmacoeconomical analysis of protease inhibitors which are applied to treatment of treatment experienced patients. Farmatsevtychnyi Zhurnal, (5), 30-36. Retrieved from https://pharmj.org.ua/index.php/journal/article/view/723
Section
Original Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
